Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership

Core Insights - Evotec SE has received a US$ 5 million milestone payment from Bristol Myers Squibb due to the FDA's acceptance of an Investigational New Drug application [1] - The milestone payment is part of a strategic collaboration focused on protein degradation, specifically involving a cereblon E3 ligase modulator [1] - A Phase 1 clinical trial for the drug candidate is anticipated to commence in 2026 [1]